跳至主要内容
临床试验/NL-OMON40709
NL-OMON40709招募中4 期

Comparison of Titanium-Nitride-Oxide coated Bio-Active-Stent (Optimax*) to the Drug (Everolimus) -Eluting Stent (Synergy*) in Acute Coronary Syndrome - TIDES-ACS

S0 个研究点目标入组 500 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
S
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients presenting with non ST-elevation or ST-elevation acute coronary syndrome

排除标准

  • - Age < 18 years
  • - Expected survival < 1 year
  • - Allergy to aspirin, clopidogrel, prasugrel or ticagrelol
  • - Allergy to heparins, glycoprotein IIb/IIIa inhibitors or bivalirudin
  • - Allergy to everolimus
  • - Active bleeding or significant increased risk of bleeding
  • - Stent length longer than 28 mm needed
  • - Stent diameter > 4.0 mm needed
  • - Previous coronary artery bypass surgery (CABG)
  • - Aorto-ostial lesion
  • - Previous coronary stenting of the target vessel
  • - Thrombolysis therapy
  • - Cardiogenic shock
  • - Planned surgery within 12 months of PCI unless the dual antiplatelet therapy could be maintained throughout the perisurgical period

研究者

发起方
S

相似试验